GEN Exclusives

More »

GEN News Highlights

More »
Feb 7, 2011

Novasep Gains Access to instrAction's Technology for Purification of Taxane APIs and Intermediates

  • Novasep and instrAction have broadened their existing API purification technology alliance to cover taxane drugs. Novasep says the extended collaboration means it will be able to develop and operate or supply optimized large-scale chromatography processes for the purification of taxane-based APIs and intermediates, utilizing instrAction’s stationary phases. The firms inked their original alliance covering nonchiral chromatography in July 2010.

    Germany-based instrAction develops and manufactures “Instruction® Receptor Phases” as novel API-selective resins for chromatography. It claims the Instruction technology enables the immobilization of a wide variety of functional ligands on a polymer network coated on very different porous backbone materials. The overall platform allows small molecules as well as high molecular weight molecules to be separated by highly selective reversible interactions. The firm has synthesized a family of selective stationary phases that it claims demonstrates strong potential for the purification of various taxanes.  

    The latest agreement means Novasep will be able to access instrAction’s technology to develop a multistep synthesis or semi-synthesis, and optimize purification steps using its partner’s set of taxane-selective chromatography stationary phases. The resulting optimized process can then be scaled up for clinical and commercial-scale purification. Alternatively, Novasep notes, it can supply the process to its customers, as a combination of its own Prochrom® HPLC columns and systems, with instrAction’s selective stationary phases.

    “Thanks to instrAction’s highly selective chromatographic stationary phases and Novasep’s 20 years experience in taxane synthesis and purification, we are looking to see a paradigm shift in solutions for our customers worldwide as a result of this collaboration,” comments René De Vaumas executive vp for business development at Novasep Synthesis.

    Novasep develops and manufactures taxane-based APIs and intermediates at its FDA-inspected, SafeBridge-certified site at Le Mans in France.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Climate Change and Disease

Are the incursions of dengue fever and West Nile virus into North America just the tip of the iceberg of insect-borne diseases that are migrating due to a warming planet?